[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606468":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":10,"centralContacts":36,"locations":10,"responsibleParty":42,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Acute Myocarditis",null,"Children (1-18 years) diagnosed with acute myocarditis, typically following viral illness, presenting with fever, chest pain, heart failure symptoms, or arrhythmias. Diagnosis supported by elevated cardiac biomarkers, echocardiographic findings of LV dysfunction, and ECG changes. Management includes standard medical therapy (inotropes, ACE inhibitors, beta-blockers) and in some cases corticosteroids or IVIG depending on severity.",[13,14],"Other: Standard Medical Therapy","Drug: Standard Medical Therapy",{"label":16,"type":10,"description":17,"interventionNames":18},"Fulminant Myocarditis","Children presenting with sudden, severe myocarditis characterized by rapid onset of cardiogenic shock, severe LV dysfunction, or multi-organ involvement. Diagnosis based on clinical picture, elevated biomarkers, echocardiography, and ECG. Management frequently requires intensive care, high-dose inotropes, and may include IVIG, corticosteroids, and mechanical circulatory support such as ECMO if indicated.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Chronic Active Myocarditis","Children with ongoing inflammatory myocarditis lasting weeks to months, presenting with persistent heart failure symptoms, arrhythmias, or progressive LV dysfunction. Diagnosis confirmed by echo and biomarkers, sometimes MRI. Treatment includes standard therapy for heart failure plus immunomodulation with corticosteroids and\u002For IVIG in selected cases. Close monitoring is required to prevent progression.",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Chronic Persistent Myocarditis","Children with a long-term, indolent course of myocarditis, often progressing toward dilated cardiomyopathy. Patients present with signs of chronic heart failure, reduced EF, and persistent LV dilation. Management includes conventional heart failure therapy (ACE inhibitors, beta-blockers, diuretics, inotropes as needed). Corticosteroids or IVIG may be used in selected patients based on clinical status. Long-term follow-up is required.",[13,14],[28,32],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"Standard Medical Therapy","All enrolled children will receive standard medical therapy tailored to clinical status. This includes inotropes (e.g., dopamine, dobutamine, milrinone), ACE inhibitors, beta-blockers, and\u002For diuretics as indicated. Treatment is supportive and adjusted according to severity of cardiac dysfunction and hemodynamic status. The goal is to stabilize heart failure, improve cardiac output, and prevent progression to dilated cardiomyopathy.",[9,20,24,16],{"type":33,"name":29,"description":34,"armGroupLabels":35,"otherNames":10},"DRUG","All enrolled children will receive standard medical therapy tailored to clinical status. This includes inotropes (dopamine, dobutamine, milrinone), ACE inhibitors, beta-blockers, and\u002For diuretics as indicated. Therapy is supportive and adjusted according to severity of cardiac dysfunction and hemodynamic status to stabilize heart failure, improve cardiac output, and prevent progression to dilated cardiomyopathy.\n\n2️⃣ Intervention 2",[9,20,24,16],[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Dr. Elshymaa Abdelmged Abdelmenaem, resident","CONTACT","01022507912","alshymabdalmjyd731@gmail.com",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Elshymaa Abdelmged Abdelmenaem","resident , pediatric department","100606468","outcome-of-clinical-phenotypes-of-pediatric-myocarditis-at-assiut-university-children-hospital-100606468",false,"NCT07175948","Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital","Outcome of Different Clinical Phenotypes of Myocarditis in Children Admitted to Assiut University Children Hospital","PED-MYO","Inclusion Criteria:\n\n* • Children aged between 1 to 18 years.\n\n  * Children diagnosed with myocarditis based on clinical presentation, echocardiography, and cardiac biomarkers, ECG and MRI (if available)\n\nExclusion Criteria:\n\n* • Children with congenital heart disease.\n\n  * Known cardiomyopathy unrelated to myocarditis.","ALL","1 Year","18 Years",{"count":58,"type":59},100,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the clinical phenotypes, management approaches, and outcomes of myocarditis in children admitted to Assiut University Children's Hospital. Myocarditis is an inflammatory disease of the heart muscle that can present in different clinical forms, including acute, fulminant, chronic active, and chronic persistent types. These forms vary in severity, treatment needs, and long-term outcomes.\n\nChildren aged 1-18 years who are diagnosed with myocarditis based on clinical findings, cardiac biomarkers, echocardiography, and electrocardiography (with MRI when available) will be included. Patients with congenital heart disease or cardiomyopathy unrelated to myocarditis will be excluded.\n\nThe study will follow eligible patients prospectively over a 12-month period. Detailed clinical assessment, laboratory tests, echocardiographic findings, and management strategies will be recorded. Special attention will be given to the role of corticosteroids and intravenous immunoglobulin (IVIG) in treatment. Outcomes including recovery of cardiac function, need for intensive care, and survival will be assessed.\n\nBy analyzing the clinical presentation, treatment, and prognosis of different myocarditis phenotypes, this study aims to improve the understanding of disease patterns in children and provide evidence to guide future management.",[63,64],"Myocarditis","Myocarditis Acute",[66,67],"Viral Myocarditis","Cardiogenic Shock","NOT_YET_RECRUITING","2025-09-14",{"date":71,"type":72},"2025-09-16","ACTUAL",{"date":74,"type":59},"2026-06-01",{"date":76,"type":59},"2027-08-01",{"name":5,"class":6}]